UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange
Act of 1934
Date of Report: November 21, 2016
Commission
File Number: 001-36891
|
Cellectis S.A. |
|
(Exact Name of registrant as specified in its charter) |
|
8, rue de la Croix Jarry |
|
75013 Paris, France |
|
+33 1 81 69 16 00 |
|
(Address of principal executive office) |
Indicate by
check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form
20-F ☑
Form 40-F ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
EXHIBIT INDEX
|
Exhibit |
Title |
|
99.1 |
Press release, dated November 21, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CELLECTIS S.A. |
||
| (Registrant) | ||
|
November 21, 2016 |
By: |
/s/ André Choulika |
|
André Choulika |
||
|
|
Chief Executive Officer |
|
3
Exhibit 99.1
Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY
NEW YORK--(BUSINESS WIRE)--November 21, 2016--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that the Company will participate in the upcoming Oppenheimer Life Sciences Summit being held on November 29, 2016 at the Sofitel Hotel in New York City.
Cellectis will be presenting at the Piper Jaffray 28th Annual Health Care Conference. Cellectis presentation will take place on November 30, 2016 at 8:00AM US Eastern Time in Lotte New York Palace - 455 Madison Ave, Track Three - Holmes 1 - 4th Floor.
A live webcast will be available at http://edge.media-server.com/m/p/xbcsg2nz
The replay is available via the same link.
About Cellectis
Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.
Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.
Disclaimer
This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties include, but are not limited to, the risk that the preliminary results from our product candidates will not continue or be repeated, the risk of not obtaining regulatory approval to commence clinical trials on the UCART product candidates, the risk that any one or more of our product candidates will not be successfully developed and commercialized. Further information on the risks factors that may affect company business and financial performance, is included in filings Cellectis makes with the Security Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
CONTACT:
Media:
Jennifer Moore, 917-580-1088
VP of
Communications
media@cellectis.com
or
Caitlin Kasunich,
212-896-1241
KCSA Strategic Communications
ckasunich@kcsa.com
or
IR:
Simon
Harnest, 646-385-9008
VP of Corporate Strategy and Finance
simon.harnest@cellectis.com